Views

CrossRef citations to date

Altmetric

Letters to the Editor

Randomized phase 1 study of sequential (“primed”) vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasm

Raffaele PalmieriClinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA; View further author information

Sarah A. BuckleyClinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA; View further author information

Megan OthusPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; View further author information

Anna B. HalpernClinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA; ;Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA; View further author information

Mary-Elizabeth M. PercivalClinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA; ;Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA; View further author information

Bart L. ScottClinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA; ;Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA; View further author information

Paul C. HendrieDepartment of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA; ;Seattle Cancer Care Alliance, Seattle, WA, USA; View further author information

Pamela S. BeckerClinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA; ;Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA; View further author information

Vivian G. OehlerClinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA; ;Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA; View further author information

Elihu H. EsteyClinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA; ;Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA; View further author information

Roland B. WalterClinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA; ;Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA; ;Department of Pathology, University of Washington, Seattle, WA, USA; ;Department of Epidemiology, University of Washington, Seattle, WA, USACorrespondence[email protected]
View further author information

show all

Click to increase image sizeClick to decrease image size

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

The conduct of the clinical trial was partially funded by Protocol Specific Research Support from the Fred Hutchinson/University of Washington Cancer Consortium Cancer Center Support Grant of the National Institutes of Health (P30-CA015704). S.A.B. was supported by a fellowship training grant from the National Heart, Lung, and Blood Institute/National Institutes of Health (NHLBI/NIH: T32-HL007093). The funding sources played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. Clinicaltrials.gov identifier: NCT02921061

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Randomized phase 1 study of sequential (“primed”) vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasm

Information for

Open access

Opportunities

Help and information

Randomized phase 1 study of sequential (“primed”) vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasm

Disclosure statement

Additional information

Funding

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature